BiotechTube

ONO-2952 + ONO-2952 Matching Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome (IBS)

Conditions

Irritable Bowel Syndrome (IBS)

Trial Timeline

Apr 1, 2013 → —

NCT ID
NCT01844180

About ONO-2952 + ONO-2952 Matching Placebo

ONO-2952 + ONO-2952 Matching Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Irritable Bowel Syndrome (IBS). The current trial status is completed. This product is registered under clinical trial identifier NCT01844180. Target conditions include Irritable Bowel Syndrome (IBS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01844180Phase 2Completed
NCT01489345Phase 1Completed

Competing Products

20 competing products in Irritable Bowel Syndrome (IBS)

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52
YM060 + PlaceboAstellas PharmaPhase 3
77
Ramosetron + PlaceboAstellas PharmaApproved
85
Ramosetron + PlaceboAstellas PharmaApproved
85
YM060Astellas PharmaPhase 3
77
YM060 + placeboAstellas PharmaPhase 2
52
YM060Astellas PharmaPhase 3
77
linaclotide + PlaceboAstellas PharmaPhase 3
77
RamosetronAstellas PharmaPre-clinical
23
YM060Astellas PharmaPhase 2
52
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
52
duloxetineEli LillyApproved
85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
77
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
77
Eluxadoline + PlaceboAbbViePhase 2
52
Placebo + LinaclotideAstraZenecaPhase 3
77
TegaserodNovartisPre-clinical
23
DNK333NovartisPhase 2
52
SMS995 + PlaceboNovartisPhase 1
33
DNK333 + PlaceboNovartisPhase 2
52

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77